ZDHHC4 and neoplasm: Identifying the cell type(s) involved and the mechanism of non-canonical cross-presentation in regressor tumors can open new therapeutic avenues to stimulate the anti-tumor immune response when Batf3-driven DC1 are excluded from the tumor.